KR20210134001A - 피에이에스케이의 억제제로서 피라졸로피리딘 유도체 - Google Patents

피에이에스케이의 억제제로서 피라졸로피리딘 유도체 Download PDF

Info

Publication number
KR20210134001A
KR20210134001A KR1020217030814A KR20217030814A KR20210134001A KR 20210134001 A KR20210134001 A KR 20210134001A KR 1020217030814 A KR1020217030814 A KR 1020217030814A KR 20217030814 A KR20217030814 A KR 20217030814A KR 20210134001 A KR20210134001 A KR 20210134001A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217030814A
Other languages
English (en)
Korean (ko)
Inventor
스테판 니콜라스 알라인 보몽
자비에르 마리 복
다니엘 코마스 마르티네즈
아그네스 마리 욘쿠르
프레데릭 길버트 라베게르
미리암 로페즈 라모스
타오우에스 더말-라이프
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20210134001A publication Critical patent/KR20210134001A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217030814A 2019-02-25 2020-02-17 피에이에스케이의 억제제로서 피라졸로피리딘 유도체 Ceased KR20210134001A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (1)

Publication Number Publication Date
KR20210134001A true KR20210134001A (ko) 2021-11-08

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030814A Ceased KR20210134001A (ko) 2019-02-25 2020-02-17 피에이에스케이의 억제제로서 피라졸로피리딘 유도체

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US10392389B2 (en) * 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
EP3615538B1 (en) * 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Also Published As

Publication number Publication date
CA3130154A1 (en) 2020-09-03
TW202045505A (zh) 2020-12-16
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
ES2963409T3 (es) 2024-03-27
MX2021010093A (es) 2021-09-21
BR112021016642A2 (pt) 2021-11-03
IL285751A (en) 2021-10-31
US20220144823A1 (en) 2022-05-12
PH12021552032A1 (en) 2022-11-14
AU2020229041A1 (en) 2021-10-21
WO2020173739A1 (en) 2020-09-03
EP3931191A1 (en) 2022-01-05
GB201902490D0 (en) 2019-04-10
CN113474344A (zh) 2021-10-01
JP2022525121A (ja) 2022-05-11
EP3931191B1 (en) 2023-10-04
CO2021010485A2 (es) 2021-08-19
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
JP6463631B2 (ja) Ｇｐｒ−１１９のモジュレータとしての新規化合物
KR101650981B1 (ko) Ｐａｓｋ의 억제를 위한 복소환 화합물
TWI461425B (zh) 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
TWI648273B (zh) 作為激酶抑制劑之雜環醯胺類（三）
CN103153968B (zh) 三唑衍生物及含有其的具有镇痛作用的药物组合物
JP5715713B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子
KR102638253B1 (ko) C5a 억제제로서의 6-5 융합 고리
KR20080081203A (ko) Ｐｐａｒ 조절제로서의 폴리시클릭1,2,3,4-테트라히드로-이소퀴놀린 유도체 및 이를 포함하는조성물
MX2011000392A (es) 4-fenoxi-metil-piperidinas como moduladoras de la actividad de gpr119.
JP2011513234A (ja) Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
JPWO2007007910A1 (ja) ヘテロ環置換ベンズイミダゾール誘導体
TW201402572A (zh) 哌啶基吡唑并吡啶衍生物
CN102617548A (zh) 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
AU2021382769B2 (en) Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
CN107250137A (zh) 作为长效dpp‑iv抑制剂的取代的氨基六元饱和杂脂环类
TW202332436A (zh) 治療用化合物
KR20210134001A (ko) 피에이에스케이의 억제제로서 피라졸로피리딘 유도체
TW201712012A (zh) ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
CN105646492B (zh) 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
TW202220961A (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
RU2833422C1 (ru) Производные дигидроизохинолинона и изоиндолинона и их применение
KR20200118005A (ko) 통증 치료용 화합물 및 조성물
AU2024390965A1 (en) Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025117616A1 (en) Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
KR20110109917A (ko) 신규한 퀴녹살린 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210924

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250302

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D